Public list Pharma Startups (4732):
Inagen was formed in 2007 to develop therapies for viral diseases. The company's primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for effective treatment to eradicate this serious disease.
Company (Alive / Active)
150 Allens Creek Road
New York, United States
|Investor||Investor Type||Location||Participating Rounds|
|Boston, Massachusetts, United States||Alive / Active||Intarcia Therapeutics is a biopharmaceutical company developing therapies to ensure the best treatment outcome by optimizing patient convenience and adherence. Intarcia is addressing challenging diseases that require long-term chronic therapy by enhancing efficacy and reducing the burden therapies often place on the patient's life. Intarcia's drug development expertise and competitive edge is demonstrated by its ability to stabilize macromolecules and to deliver them in a constant and consistent...Show all||Login to see details|
|Louisville, Colorado, United States||IPO / Went public||GlobeImmune is a biopharmaceutical company focused on developing products for the treatment of infectious disease and and oncology based on its proprietary Tarmogen platform. Tarmogens are believed to activate the immune system by stimulating cellular immunity, known as T cell immunity, in contrast to traditional vaccines that predominately stimulate antibody production. To date, Tarmogen product candidates have been generally well tolerated in clinical trials for multiple disease indications an...Show all||Login to see details|